Comparative Improvement in Health-Related Quality of Life With Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis
Advanced therapies were associated with improvements in HR-QoL after induction and maintenance. Upadacitinib 45 mg and infliximab 10 mg/kg ranked highest after induction and maintenance, respectively.
Authors
- María Laura Parks (ORCID: https://orcid.org/0000-0003-0775-0974)
- Pablo A. Olivera (ORCID: https://orcid.org/0000-0002-2740-6102)
- Ignacio Zubiaurre (ORCID: https://orcid.org/0000-0001-8334-9934)
- Laura E. Targownik (ORCID: https://orcid.org/0000-0002-4366-9076)
- Juan S. Lasa (ORCID: https://orcid.org/0000-0003-0957-5591)
- Laurent Peyrin-Biroulet
Institutions
- Hospital Británico (UY)
- Mount Sinai Hospital (CA)
- Inserm (FR)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- McGill University Health Centre (CA)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Sinai Health System (CA)
- Clinique Hartmann (FR)
- Hospital Británico de Buenos Aires (AR)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.14309/ajg.0000000000003333
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 7.27